Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress GlobeNewswire August 06, 2025 Strong execution of two ongoing Phase 3 trials of daraxonrasib; for RASolute 302, company is winding down enrollment in U.S. and expects to complete enrollment of the trial this year FDA Breakthrough Therapy Designations granted for two RAS(ON) […]
Edgewise Therapeutics, Inc. (“Edgewise” or the “Company”), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on July 31, 2025, Edgewise granted inducement stock options to purchase a total of 84,250 shares of Edgewise's common stock and awards of inducement restricted stock units
(CNSX:GTII.CN),(OTC US:GTBIF),(Other OTC:GTBIF), CHICAGO and VANCOUVER, British Columbia, Aug. 06, 2025 (GLOBE NEWSWIRE) — Green Thumb Industries Inc. (“Green Thumb” or the “Company”) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of RISE Dispensaries, today reported its financial results for the quarter ended June 30, 2025. Financial results are
(NASDAQ:OM), SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) — Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the second quarter ended June 30, 2025. Second Quarter and Recent Highlights Net revenue of $31.4 million grew 15%
Green Thumb Industries Reports Second Quarter 2025 Results GlobeNewswire August 06, 2025 CHICAGO and VANCOUVER, British Columbia, Aug. 06, 2025 (GLOBE NEWSWIRE) — Green Thumb Industries Inc. (“Green Thumb” or the “Company”) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of RISE Dispensaries, today reported its financial results for
Outset Medical Second-Quarter Results Demonstrate Continued Momentum, Punctuated by Strong Revenue Growth, Console Placements and Utilization Company raises 2025 revenue guidance to a range of $122 million to $126 million GlobeNewswire August 06, 2025 SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) — Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind
Second quarter 2025 total revenue of $315 million Second quarter 2025 International revenue of $41 million Second quarter 2025 adjusted gross margin(1) of 49% Awarded license to operate in Turkey's nascent medical cannabis market Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading international provider of consumer products in cannabis, today
Q2 2025 Revenue, Net Income, and Adjusted EBITDA Exceeded Guidance Simplification Continues with Sale of Graduate School USA, Redemption of All Preferred Equity, and Sale of Two Administrative Office Buildings American Public Education, Inc. (Nasdaq: APEI), a portfolio of education companies providing online and campus-based postsecondary education to over 105,000 students through three subsidiary institutions,
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Canaccord Genuity 45th Annual Growth Conference at 8:00 a.m. ET on Wednesday, August 13, 2025. Chief Executive Officer Kyle Gano and Vice-President of Investor Relations Todd Tushla will present at the conference. https://mma.prnewswire.com/media/678850/Neurocrine_Biosciences_Logo.jpg The live webcast can be accessed on Neurocrine Biosciences' website under Investors at
Xtant Medical Holdings, Inc.(NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced thatSean Browne, CEO andScott Neils, CFO will be attending the following upcoming conference: https://mma.prnewswire.com/media/2725938/XTNT_Logo.jpg Event: CG 45th AnnualGrowth ConferenceDate:August 12, 2025 at 3:30pm ETLocation:Boston, MAFormat: 1×1 Meetings & Presentation